$239.99 1.1%
PEN Stock Price vs. AI Score
Data gathered: January 2

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Penumbra (PEN)

Analysis generated February 10, 2024. Powered by Chat GPT.

Penumbra is a global healthcare company that designs, develops, manufactures, and markets innovative medical devices. The company is specialized in products that address challenging medical conditions in markets such as neuro and peripheral vascular conditions. Penumbra's commitment to improving patient outcomes through cutting-edge technology has positioned it as a leader in its respective fields, fostering a reputation for innovation and quality.

Read full AI stock Analysis

Stock Alerts - Penumbra (PEN)

company logo Penumbra | December 25
Employee Rating is down by 3.1% over the last month.
company logo Penumbra | December 24
Insider Alert: Elsesser Adam is selling shares
company logo Penumbra | December 11
Price is up by 5.6% in the last 24h.
company logo Penumbra | December 4
Insider Alert: Roberts Johanna is continuing selling shares

About Penumbra

Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally.


Penumbra
Price $239.99
Target Price Sign up
Volume 145,810
Market Cap $9.11B
Year Range $163.64 - $253.66
Dividend Yield 0%
PE Ratio 269.86
Analyst Rating 75% buy
Industry Medical Devices

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '24301M101M200M30M36M0.850
Q2 '24299M77M-77M-60M3.6M0.640
Q1 '24279M98M181M11M18M0.410
Q4 '23285M98M187M54M41M0.760
Q3 '23271M93M178M9.2M15M0.670

Insider Transactions View All

Elsesser Adam filed to sell 851,782 shares at $240.8.
December 23 '24
Elsesser Adam filed to sell 837,582 shares at $244.8.
December 23 '24
Elsesser Adam filed to sell 838,611 shares at $243.9.
December 23 '24
Elsesser Adam filed to sell 847,744 shares at $242.1.
December 23 '24
Elsesser Adam filed to sell 842,309 shares at $242.9.
December 23 '24

What is the Market Cap of Penumbra?

The Market Cap of Penumbra is $9.11B.

What is Penumbra's PE Ratio?

As of today, Penumbra's PE (Price to Earnings) ratio is 269.86.

What is the current stock price of Penumbra?

Currently, the price of one share of Penumbra stock is $239.99.

How can I analyze the PEN stock price chart for investment decisions?

The PEN stock price chart above provides a comprehensive visual representation of Penumbra's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Penumbra shares. Our platform offers an up-to-date PEN stock price chart, along with technical data analysis and alternative data insights.

Does PEN offer dividends to its shareholders?

As of our latest update, Penumbra (PEN) does not offer dividends to its shareholders. Investors interested in Penumbra should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Penumbra?

Some of the similar stocks of Penumbra are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.